Hematology-Oncology Clinics of North America

Papers
(The TQCC of Hematology-Oncology Clinics of North America is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Epidemiology of Melanoma47
Molecular Pathogenesis of Mantle Cell Lymphoma44
Biology of Melanoma42
Screening for Colorectal Cancer38
Diagnosis and Staging of Bladder Cancer36
Factor XI Deficiency35
The Epidemiology of Bladder Cancer29
Nasopharyngeal Carcinoma and Its Association with Epstein-Barr Virus22
Epidemiology of Follicular Lymphoma22
Lip and Oral Cavity Squamous Cell Carcinoma20
Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm19
Overview of Myeloproliferative Neoplasms19
Blastoid Mantle Cell Lymphoma19
Disorders of Fibrinogen and Fibrinolysis18
Colorectal Cancer in Younger Adults17
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma17
CD123 as a Therapeutic Target Against Malignant Stem Cells17
Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms16
Von Willebrand Disease16
Genetics of Myeloproliferative Neoplasms14
Blastic Plasmacytoid Dendritic Cell Neoplasm in Children14
The Epidemiology of Central Nervous System Tumors14
Hereditary Colorectal Cancer14
Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm14
Blastic Plasmacytoid Dendritic Cell Neoplasm13
Racial and Ethnic Disparities in Colorectal Cancer Screening and Outcomes13
Rare Coagulation Factor Deficiencies (Factors VII, X, V, and II)13
Acquired von Willebrand Syndrome13
The Role of Megakaryocytes in Myelofibrosis13
Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm13
Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm13
The Microenvironment in Myeloproliferative Neoplasms12
Current Therapy and Emerging Intravesical Agents to Treat Non–Muscle Invasive Bladder Cancer12
Gene Therapy for Hemoglobinopathies12
Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm12
Cellular Therapy and Cytokine Treatments for Melanoma11
Pancreatic Adenocarcinoma11
Current Clinical Investigations in Myelofibrosis11
Acquired Hemophilia A11
Developing Precision Medicine for Bladder Cancer10
Primary Central Nervous System Lymphomas10
Impact of Diet and Exercise on Colorectal Cancer10
Central Nervous System Metastases10
Immunotherapy for Head and Neck Cancer9
Structural Racism and Impact on Sickle Cell Disease9
Minimal Residual Disease in Mantle Cell Lymphoma9
A Curative DNA Code for Hematopoietic Defects9
Managing Recurrent Metastatic Head and Neck Cancer9
Cancer of the Paranasal Sinuses9
Neurocognition and Health-Related Quality of Life Among Patients with Brain Tumors9
Go the Distance8
Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis8
The Process of Amyloid Formation due to Monoclonal Immunoglobulins8
Salivary Gland Cancers8
Systemic Amyloidosis Due to Clonal Plasma Cell Diseases8
Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia8
Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?8
Preclinical Models for Bladder Cancer Research8
Factor XIII Deficiency8
Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer8
Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm8
Systemic Amyloidosis due to Low-Grade Lymphoma8
Gene Therapy and Gene Editing for β-Thalassemia8
Stem Cell Mobilization and Autologous Transplant for Immunoglobulin Light-Chain Amyloidosis7
Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms7
Cancer of the Larynx and Hypopharynx7
Neurofibromatoses7
Hemophilia A (Factor VIII Deficiency)7
Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma6
Chimeric Antigen Receptor T-cell Therapy6
Cell Cycle Dysregulation in Mantle Cell Lymphoma6
Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic Leukemia6
The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia6
Real World Outcomes of Patients with Bladder Cancer6
Update on Radiation Therapy for Central Nervous System Tumors6
Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology6
Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms6
The Clinical Phenotypes of Alpha Thalassemia6
Management of Rectal Cancer6
Autoimmune Hemolytic Anemia: Diagnosis and Differential Diagnosis6
Renal Cell Carcinoma of Variant Histology6
Application of Stem Cell Therapy in Myelofibrosis6
Hemophilia B (Factor IX Deficiency)6
Imaging Advances for Central Nervous System Tumors6
Adult Evans' Syndrome6
Watch and Wait in Mantle Cell Lymphoma6
Is There a Role for Immunotherapy in Central Nervous System Cancers?5
Disparities and Inequities Among Patients with Central Nervous System Tumor5
Nonoperative Management for Rectal Cancer5
Molecular Basis and Genetic Modifiers of Thalassemia5
Immune Therapy for Chronic Lymphocytic Leukemia5
Ex Vivo and In Vivo Gene Therapy for Mucopolysaccharidoses: State of the Art5
Robotic and Endoscopic Approaches to Head and Neck Surgery5
Evolution of Gene Therapy, Historical Perspective5
Liver and Gastrointestinal Involvement5
Combinatorial Approaches to the Treatment of Advanced Melanoma5
Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer5
The Biological Basis of Histologic Transformation5
Systemic Amyloidosis Caused by Monoclonal Immunoglobulins5
The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer5
Liver and Gastrointestinal Involvement5
Gene Therapy for Inborn Errors of Immunity5
Fetal Hemoglobin Regulation in Beta-Thalassemia5
Advanced Melanoma5
The Evolving Landscape of Drug Therapies for Sickle Cell Disease4
Approach to the Initial Treatment of Older Patients with Mantle Cell Lymphoma4
Supportive Care for Patients with Systemic Light Chain Amyloidosis4
Systemic Amyloidosis due to Monoclonal Immunoglobulins4
State of Melanoma4
Biology and Treatment of Meningiomas4
Quality of Life in Sickle Cell Disease4
Surgical Management of the Axilla for Breast Cancer4
Red Cell Antigens and Antibodies4
Cancer of the Oropharynx and the Association with Human Papillomavirus4
Immunotherapy-associated Autoimmune Hemolytic Anemia4
Surgery for Bladder and Upper Tract Urothelial Cancer4
Genetic Modifiers of Sickle Cell Disease4
Immune Checkpoint Therapies for Melanoma4
Blastic Plasmacytoid Dendritic Cell Neoplasm4
Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer4
Future Perspectives4
Cytogenetics of Blastic Plasmacytoid Dendritic Cell Neoplasm4
Emerging Therapies in β-Thalassemia4
Quality of Life in Myeloproliferative Neoplasms4
Hematopoietic Stem Cell Transplantation in Thalassemia4
Molecular Biology of Bladder Cancer4
Accelerated and Blast Phase Myeloproliferative Neoplasms4
Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia4
Treatment of Histologic Transformation4
Role of Ovarian Suppression in Early Premenopausal Breast Cancer4
Epigenetic Dysregulation of Myeloproliferative Neoplasms4
Emerging Targeted Therapy for Bladder Cancer4
Current Therapy for Metastatic Urothelial Carcinoma4
0.056552171707153